Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 17/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 17/20 | 0.70 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.60 |
| ▸ | HRH2 | P25021 | 4/20 | 0.58 |
| ▸ | HTR2C | P28335 | 4/20 | 0.58 |
| ▸ | HRH1 | P35367 | 4/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.58 |
| ▸ | HTR1A | P08908 | 3/20 | 0.58 |
| ▸ | HTR2A | P28223 | 3/20 | 0.58 |
| ▸ | HTR2B | P41595 | 3/20 | 0.58 |
| ▸ | HTR1E | P28566 | 3/20 | 0.58 |
| ▸ | HTR1B | P28222 | 2/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | DRD1 | P21728 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.57 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.57 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30645345 | 1.00 | TMEM97 (0.70) | TMEM97SIGMAR1ESR2HRH2HTR2C | |
| SCHEMBL1299903 | 0.95 | TMEM97 (0.70) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL30515329 | 0.95 | TMEM97 (0.70) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL21800344 | 0.89 | TMEM97 (0.66) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL4011213 | 0.88 | TMEM97 (0.65) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL324228 | 0.88 | TMEM97 (0.67) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL30031624 | 0.88 | TMEM97 (0.67) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL18530311 | 0.88 | TMEM97 (0.67) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL19622378 | 0.88 | TMEM97 (0.71) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL1027550 | 0.88 | TMEM97 (0.67) | TMEM97SIGMAR1HRH2HTR2CHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-04-11 | — | — | US | disclosed |
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
| EP-2114890-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008097428-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2008-08-14 | — | — | WO | disclosed |
| EP-0828754-B1 | DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE | PFIZER (US) | 2005-02-02 | — | — | EP | disclosed |
| US-5936089-A | PIPERIDINE DERIVATIVES; BONE DISORDERS; OBESITY; AGING; CACHEXIA ASSOCIATED WITH AIDS AND CANCER | PFIZER INC (US) | 1999-08-10 | — | — | US | disclosed |
| EP-0828754-A1 | DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE | PFIZER INC. (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996038471-A1 | DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE | PFIZER INC. (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1996035713-A1 | DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE | PFIZER, INC. (US) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GCGR, GPR65 | TMEM97 318/4885SIGMAR1 1466/4885ESR2 218/4885 |
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | PSMG3, MYCBP2, PSME2 | TMEM97 1702/4885SIGMAR1 3460/4885ESR2 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.